ArticleFrontiers in oncology2022

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab.

Ahmad Y Abuhelwa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.